<SEC-DOCUMENT>0001171843-25-007453.txt : 20251120
<SEC-HEADER>0001171843-25-007453.hdr.sgml : 20251120
<ACCEPTANCE-DATETIME>20251120081504
ACCESSION NUMBER:		0001171843-25-007453
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20251120
FILED AS OF DATE:		20251120
DATE AS OF CHANGE:		20251120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evaxion A/S
		CENTRAL INDEX KEY:			0001828253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39950
		FILM NUMBER:		251501046

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		PROVINCE COUNTRY:   	G7
		BUSINESS PHONE:		4552656554

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		PROVINCE COUNTRY:   	G7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Evaxion Biotech A/S
		DATE OF NAME CHANGE:	20201014
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_112025.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>For the month of November 2025</strong></p><p style="text-align: center;">Commission File Number: <strong>001-39950</strong></p><p style="text-align: center;"><font><font style="font-size: 12pt;"><strong>Evaxion A/S</strong></font></font><br />(Exact Name of Registrant as Specified in Its Charter)</p><p style="text-align: center;"><strong>Dr. Neergaards Vej 5f<br />DK-2970&#160;Hoersholm<br />Denmark</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p><p style="text-align: center;">Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p><!--<p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <u></u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <u></u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.&#160;</p>--></p><hr style="break-after: page;" noshade="noshade" /><p style="text-align: center;"><strong>INCORPORATION BY REFERENCE</strong></p><p>This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S&#8217;s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</p><p><font><p><strong>Press Release</strong></p><p>On November 20, 2025, Evaxion A/S (the &#8220;Company&#8221;), a clinical-stage TechBio company specializing in developing AI-Immunology&#8482; powered vaccines, issued a press release titled "Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.</p><p><strong>Exhibits</strong></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Exhibit Number</strong></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Description</strong></font></td></tr><tr><td>&#160;</td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;"><a href="exh_991.htm">Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1</a> </font></td></tr></table></font></p><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline; text-align: left;" align="center" width="47%"><strong>Evaxion A/S</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: November 20, 2025</td><td width="6%">&#160;</td><td width="6%">By:</td><td style="text-decoration: underline; text-align: left;" align="center" width="47%">/s/ Birgitte R&#248;n&#248;&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">Birgitte R&#248;n&#248;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">Interim Chief Executive Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><strong>Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1</strong></p><p style="text-align: center;" ></p><p>
 <ul><li style="text-align:justify;"><b>Evaxion&#8217;s AI-Immunology&#153; platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models&#160;</b></li><li style="text-align:justify;"><b>EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens</b></li><li style="text-align:justify;"><b>Evaxion&#8217;s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen demonstrates superior performance compared to the traditional gB antigen, including enhanced CMV neutralization</b></li><li style="text-align:justify;"><b>Preclinical advancement is ongoing with continued optimization and investigation of AI-derived antigens </b></li><li style="text-align:justify;"><b>CMV remains an area of huge unmet medical need. Despite decades of research, no CMV vaccine has been approved to date, underscoring the importance of these new discoveries</b><br ><br ></li></ul>  <p align="justify">COPENHAGEN, Denmark, November 20, 2025 - Evaxion A/S (NASDAQ: EVAX) (&#8220;Evaxion&#8221;), a clinical-stage TechBio company specializing in developing AI-Immunology&#153; powered vaccines, is successfully advancing its novel multi-component cytomegalovirus (CMV) vaccine program, EVX-V1, with new data demonstrating protective effects of lead antigens in the program.</p>  <p align="justify">With our AI-Immunology&#153; platform, we have uncovered novel antigens that are entirely new to the CMV vaccine research field. These previously unexplored CMV-antigens induce specific immune responses, inhibit viral infection and reduce cell-to-cell spread in cellular and animal viral infection models. These are significant discoveries since very few protective CMV-antigens have been identified despite decades of intensive research.</p>  <p align="justify">The new findings add to earlier data demonstrating that Evaxion&#8217;s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen effectively neutralizes CMV. This enhanced gB antigen constitutes a key component of EVX-V1, which combines AI-discovered antigens with AI-optimized conventional antigens to attack the virus from multiple, complementary angles. This broader multi-targeted strategy is expected to strengthen the protective potential of the future vaccine.</p>  <p align="justify">&#8220;We are very excited by the new data demonstrating the unique capability of AI-Immunology&#153; to find novel protective vaccine targets where no others have been able to do so. This further exemplifies how our technology enables the discovery of potentially groundbreaking new therapies and offers hope for improved prevention of CMV infections, an area of significant medical need&#8221;, says Birgitte R&#248;n&#248;, CSO and interim CEO of Evaxion.</p>  <p align="justify">Evaxion continues the preclinical advancement of the EVX-V1 program with further identification, investigation and optimization of antigens. In parallel, Evaxion is actively exploring strategic partnerships to accelerate development and ensure a seamless transition into non-clinical and clinical phases.</p>  <p align="justify"><b>About cytomegalovirus (CMV)</b><br >About 1 in 200 babies is born with congenital CMV infection. About 1 in 5 babies with the infection will have congenital disabilities or other long-term health problems. CMV infects approximately 60% to 70% of adults in developed countries and nearly 100% in developing economies, driving demand for CMV treatment. Despite decades of research, no CMV vaccine has been approved to date.</p>  <p align="justify">CMV treatment market size was valued at $474.6 million in 2023 and is anticipated to register an annual growth (CAGR) of 6.6% between 2024 and 2032. This growth is propelled by increasing awareness and prevalence of CMV infection and the development of new and effective treatments.</p>  <p align="justify">CMV is the most complex of all herpes viruses and is a widespread infection transmitted in body fluids. Once infected, the virus stays for life. People with weakened immune systems, including organ transplant patients, can develop severe symptoms affecting, for example, eyes, lungs, and liver, and congenitally infected babies may suffer from intellectual disability and loss of vision and hearing.</p>  <p align="justify"><b>Contact information</b>&#160;<br >Evaxion A/S<br >Mads Kronborg<br >Vice President, Investor Relations &amp; Communication<br >+45 53 54 82 96 <br >mak@evaxion.ai</p>  <p align="justify"><b>About Evaxion</b> <br >Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology&#153;. Evaxion&#8217;s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology&#153;, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients&#8217; lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology&#153; platform and vaccine pipeline, please visit our website.</p>  <p align="justify"><b>Forward-looking statement</b>&#160;<br >This&#160;announcement contains forward-looking statements&#160;within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.&#160;The words&#160;&#8220;target,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;hope,&#8221; &#8220;aim,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;anticipate,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;can have,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; and other words and terms of similar meaning&#160;identify forward-looking statements.&#160;Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,&#160;the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our&#160;business from other significant geopolitical and macro-economic events;&#160;and other uncertainties affecting our business operations and financial condition.&#160;For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F&#160;and other filings&#160;with the US Securities and Exchange Commission (SEC), which are available at&#160;<b>www.sec.gov</b>.&#160;We do not assume any obligation to update any forward-looking statements except as required by law.&#160;</p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
